April 15 Plenary Congress Day 1

MORNING PLENARIES RENAISSANCE BALLROOM

Gregory Poland
08:20

Chair’s opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Brett Giroir
08:30

Strengthening the effectiveness of national, state & local efforts to improve the uptake of HPV vaccination

Panel discussion
08:45

Plenary keynote insights: What direction will vaccines take to ensure safety and mass immunization

  • Vaccine Research and Development in the Public Sector
  • What kind of regulatory and political support can we expect?
  • Prevention and pre-prepared efforts to ensure our current and future safety
  • Vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development
Panel discussion
10:45

Networking Coffee Break

INTERACTIVE ROUNDTABLES

11:45

Artificial intelligence -adopting cognitive computing across the PV landscape

11:45

Changing landscape of real-world evidence and its impact on clinical research – uncovering lab & clinical adverse events

Dr James Cummings
11:45

Developing more effective vaccines for emerging/re-emerging pandemic threats

Dr James F. Cummings, MD, President, ICON Government and Public Health Solutions – title TBC
11:45

Development of novel predictive algorithms for patient selection

Jason Berg
11:45

Identifying the ideal vaccine research site – lessons learned from the field

Senior representative, PPD
Dr Richard Kennedy
11:45

Immune Profiling - capturing the complexity of immune responses to vaccines and infections

Dr Michael Salgaller
11:45

Oncology – applying precision medicine and informatics to find the best treatment option for each patient

11:45

Overcoming obstacles to improve cold chain management of biologics

11:45

Pediatric Vaccine Trials – Recruitment and Retention

Dr Nathalie Garcon
11:45

Safety evaluation of vaccines: from now to tomorrow, new approaches and technologies?

Dr Nathalie Garcon, CSO & CEO, Bioaster
Cynthia Dukes
11:45

Seasonal vaccine studies: Critical success factors

Cynthia Dukes, VP, Scientific and Clinical Services and Head of Vaccine Center of Excellence, ICON Clinical Research – title TBC
Dr Jun Tang
11:45

When limited patient resources meet unlimited immunotherapy combinations—the strategies to develop clinical IO agents in platform studies

13:10

Networking Lunch (Exhibition Hall)

AFTERNOON PLENARIES

Panel discussion
14:40

The role of vaccines to combat antibiotic-microbial resistance

  • What can we do to manage AMR? The mis-use of Abx in bacterial and viral infections
  • How vaccine regulatory and access policies can be used to strengthen utilization of vaccines as a component of multi-pronged strategies that governments should take in their national action plans to address AMR
  • The need for a holistic and collaborative strategy including cross species considerations
Panel discussion
16:30

Networking Coffee Break

AFTERNOON PLENARIES

ONE HEALTH

Plenary afternoon day 1
17:00

The continuing instrumental role of NGOs: Making the impossible, achievable

  • What global market trends can we expect in the next 10 years? What does this mean for vaccines?
  • Impact of emerging diseases, AMR and measles outbreaks
  • Ongoing efforts towards developing world diseases and child health
  • Strengthening of primary health care systems
Plenary afternoon day 1
17:50

The resurgence of immuno-oncology – Can they hold their promise?

  • How will recent breakthroughs in immuno-oncology shape the way we design cancer vaccines and combinational treatments?
  • Are our expectations vs the reality of immunotherapies working aligned?
  • How can we better characterize post-treatment analysis of anti-tumor immune responses to develop more effective immunotherapy approaches?
  • Advancements in personalized neoantigen vaccines and novel targets
ONE HEALTH
17:50

Operational framework for strengthening human & animal public health systems at their interface

  • What tools and resources from the human health, animal health, and disaster risk reduction sectors can facilitate multi-sectoral coordination?
  • Strategy for appropriate One Health entry points and a pathway to the prevent-detect-respond-recover spectrum of preparedness
  • What public health system changes do we need to truly facilitate a One Health approach?
18:40

Chair’s Closing Remarks and Close of Congress Day 1

18:50

Pre-Awards Networking Drinks Reception (off-site)

19:30

Gala Dinner & 12th Annual ViE Awards Ceremony

last published: 25/Mar/19 10:45 GMT

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071